Advanced search
Publication Cover
Expert Review of Vaccines Volume 1, 2002 - Issue 4
Submit an article Journal homepage
28
Views
9
CrossRef citations to date
0
Altmetric
Review

Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach

Mandvi Bharadwaj CCRC.I, Queensland Institute of Medical Research, Royal Brisbane Hospital Post Office, Brisbane 4029, Queensland, Australia. [email protected]
&
Denis J Moss CCRC.I, Queensland Institute of Medical Research, Royal Brisbane Hospital Post Office, Brisbane 4029, Queensland, Australia. [email protected]
Pages 467-476 | Published online: 09 Jan 2014

References

  • Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B-lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol. Pathol 53(1), 37–42 (2000).
  • Karajannis MA, Hummel M, Anagnostopoulos I, Stein H. Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. B/ooc/89(8), 2856–2862 (1997).
  • Rickinson AB, Moss DJ. Human cytotoxic T-lymphocyte responses to Epstein-Barr virus infection. Ann. Rev Immunol 15, 405–431 (1997).
  • ••Extensive review of Cu, response to EBV.
  • Kieff E. Epstein-Barr virus and its replication. In: Field's Virology Fields BN, Knipe DM and Howley PM (Eds). Lippincott-Raven, Philadelphia, PA, USA, 2343–2396 (1996).
  • ••General overview of EBV replication and the different viral proteins.
  • Speck SH, Chatila T, Flemington E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Tends Mcrobiol 5,399–405 (1997).
  • Edson CM, Thorley-Lawson DA. Epstein- Barr virus membrane antigens: characterization, distribution and strain differences.j Viral. 39,172–184 (1981).
  • Klein G. EBV and B-cell Lymphomas. In: Herpes viruses and Immunity Medveczky PG, Friedman H, Bendinelli M (Eds). Plenum, New York, NY, USA, 165–190 (1998).
  • Murray PG, Young LS. The Role of the Epstein-Barr virus in human disease. Fmnt. Biosci 7, D519–540 (2002).
  • Chiang AK, Chan AC, Srivastava G, Ho FC. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int. j Cancer 73,332–338 (1997).
  • Shibata D, Weiss LM. Epstein-Barr virus- associated gastric adenocarcinoma. Am Pathol 140,769–774 (1992).
  • Webster-Cyriaque J, Middeldorp J, Raab- Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J. Vim!. 74,7610-7618 (2000).
  • Deshpande CG, Badve S, Kidwai N, Longnecker R. Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1 and LIVIP2A, in breast cancer cells. Lab. Invest. 82(9), 1193–1199 (2002).
  • Levitskaya J, Coram M, Levitsky V etal. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375,685–688 (1995).
  • •Lack of processing and recongition of Epstein-Barr virus nuclear antigen.
  • Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. j Viral. 75(8), 3740–3752 (2001).
  • Schoenberger SP, Toes RE, van der Voort El, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD4O-CD4OL interactions. Nature 393, 480–483 (1998).
  • Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T-lymphocyte responses. I Exp. Med. 188,2199-2204 (1998).
  • Rooney CM, Smith CA, Ng CY et al Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345,9–13 (1995).
  • ••Adoptive transfer of CD8+ CTL resolves lymphomas in patients.
  • Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T-cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Pmc. Natl Acad. Sc]. 96(18), 10391–10396 (1999).
  • ••Adoptive transfer of CD8+ CTL resolvespost-transplant lymphoproliferative disease in patients.
  • Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T-cells. Ann. Oncol S129-132 (1998).
  • ••Adoptive transfer of CD8+ CTL resolvesHodgkins disease in patients.
  • Callan NE, Annels N, Steven Net al T-cell selection during the evolution of CD8+T-cell memory in vivo. Eur. j Immunol 28, 4382–4390 (1998).
  • Tan LC, Gudgeon N, Annels NE et al. A re-evaluation of the frequency of CD8+ T-cells specific for EBV in healthy virus carriers. Immune/. 162,1827–1835 (1999).
  • •CTL response in healthy virus carriers.
  • Bharadwaj M, Burrows SR, Burrows JM, Moss DJ, Catalina M, Khanna R. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T-lymphocytes following primary Epstein-Barr virus infection. Blood 98,2588–2589 (2001).
  • ••Dynamics of cu, response duringinfectious mononucleosis and its implications.
  • Lechner F, Wong DK, Dunbar PR et al Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191,1499–1512 (2000).
  • Farrell PJ, Hollyoake M, Niedobitek G, Agathanggelou A, Morgan A, Wedderburn N. Direct demonstration of persistent Epstein-Barr virus gene expression in peripheral blood of infected common marmosets and analysis of virus-infected tissues in vivo. J. Gen. Viral 78(6), 1417–1424 (1997).
  • Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang E An animal model for acute and persistent Epstein-Barr virus infection. Science 276(5321), 2030–2033 (1997).
  • Bharadwaj M, Sherritt M, Khanna R, Moss DJ. Contrasting Epstein-Barr virus-specific cytotoxic T-cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 19,3769–3777 (2001).
  • •cu, response in healthy virus carriers and mice — implications of natural infection vemus immunization.
  • Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. I Immunol 162(5), 3063–3069 (1999).
  • Rano E, Woodland DL, Blackman MA. A mouse model for infectious mononucleosis. Immund Res. 25(3), 201–217 (2002).
  • Arrand JR. Prospects for a vaccine against Epstein-Barr virus. Cancer 1 5,188–193 (1992).
  • Morgan AJ. Epstein-Barr virus vaccines. Vaccine 10,563–571 (1992).
  • Gu SY, Huang TM, Ruan L et al First EBV vaccine trial in humans using recombinant vaccina virus expressing the major membrane antigen. Dev. Biol. Stand. 84, 171–177 (1995).
  • Epstein MA, Randle BJ, Finerty S, Kirkwood JK. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin. Exp. Immund 63(3), 485–490 (1986).
  • Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 17, 1282–1290 (1999).
  • Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv. Cancer Res. 69, 213–245 (1996).
  • Thomson SA, Elliott SL, Sherritt MA et al Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T-cell epitopes. I Immunol 157(2), 822–826 (1996).
  • •Delivery of multiple crn, epitopes by polytope technology.
  • Munz C, Bickham KL, Subklewe M et al. Human CD4(+) T-lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNAL I Exp. Med. 191(10), 1649–1660 (2000).
  • Lee SP, Constandinou CM, Thomas WA et al Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. B./oat/92,1020–1030 (1998).
  • Khanna R, Busson P, Burrows SR et al Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 58,310–304 (1998).
  • Frisan T, Sjoberg J, Doketti R et al Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86(4), 1493–1501 (1995).
  • Dukers DF, Jaspars LH, Vos W et al Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. I Pathol 190(2), 143–149 (2000).
  • Sing AP, Ambinder RF, Hong DJ etal. Isolation of Epstein-Barr virus (EBV) - specific cytotoxic T-lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Bkoc/89(6), 1978–1986 (1997).
  • Kuby J. Immunology 31r1 Edition. WH Freeman (Ed.) New York, NY, USA, (1997).
  • Rowe M, Khanna R, Jacob CA et al Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: co-ordinate upregulation of peptide transporters and HLA-class I antigen. Eur I Immunol 25(5), 1374–1384 (1995).
  • Sette A, Sidney J. Nine major HLA class I super types account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 (3-4), 201–212 (1999).
  • ••Discusses the human leukocyte antigen(HLA) supertype concept.
  • Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T-cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMPl-specific cytotoxicT- lymphocytes. Elm Immunol 28 (2), 451–458 (1998).
  • Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV) -specific cytotoxic T-lymphocytes for patients with refractory EBV-related lymphoma. Br. J. 1--Lematol 118(3), 799–808 (2002).
  • Rooney CM, Smith CA, Ng CY etal. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5), 1549–1555 (1998).

Websites

  • Aviron announces initiation of Phase 2 clinical trial with Epstein-Barr virus vaccine Mountain View, CA, USA, October 25 2000, http://wvvvv.aviron.com/pressi 102500.html.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.